NKTR - Nektar Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NKTR is currently covered by 7 analysts with an average price target of $8.35. This is a potential upside of $7.64 (1076.06%) from yesterday's end of day stock price of $0.71.

Nektar Therapeutics's activity chart (see below) currently has 124 price targets and 89 ratings on display. The stock rating distribution of NKTR is 50% HOLD, 37.5% SELL and 12.5% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 47.18% with an average time for these price targets to be met of 63.17 days.

Highest price target for NKTR is $3, Lowest price target is $3.

Most recent stock forecast was given by JESSICA FYE from JPMORGAN on 20-Nov-2023. First documented stock forecast 28-Jul-2014.

Currently out of the existing stock ratings of NKTR, 4 are a HOLD (50%), 3 are a SELL (37.5%), 1 are a BUY (12.5%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

1 years 5 months 22 days ago
(20-Nov-2023)

5/8 (62.5%)

$6.02 (54.83%)

121

Buy

$2

1 years 6 months 3 days ago
(09-Nov-2023)

0/4 (0%)

$0.61 (43.88%)

Hold

$35

1 years 6 months 4 days ago
(09-Nov-2023)

0/6 (0%)

$17.89 (104.56%)

Hold

1 years 6 months 4 days ago
(08-Nov-2023)

0/3 (0%)

$1.26 (26.58%)

Hold

$1

$-0.03 (-2.91%)

$1.5

2 years 2 days ago
(10-May-2023)

3/3 (100%)

$0.25 (33.33%)

39

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NKTR (Nektar Therapeutics) average time for price targets to be met?

On average it took 63.17 days on average for the stock forecasts to be realized with a an average price target met ratio 47.18

Which analyst has the current highest performing score on NKTR (Nektar Therapeutics) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on NKTR (Nektar Therapeutics)?

Josh Schimmer works at EVERCORE and has 3 price targets and 2 ratings on NKTR

Which analyst is the currently most bullish on NKTR (Nektar Therapeutics)?

George Farmer with highest potential upside - $45.4

Which analyst is the currently most reserved on NKTR (Nektar Therapeutics)?

Roger Song with lowest potential downside - -$0.03

Nektar Therapeutics in the News

Q1 2025 Nektar Therapeutics Earnings Call

Participants Corinne Franklin; investor relation; Nektar Therapeutics Howard Robin; President, Chief Executive Officer, Director; Nektar Therapeutics Jonathan Zalevsky; Chief Research and Development Officer; Nektar Therapeutics Sandra Gardiner; Interim Chief Financial Officer; Nektar Therapeutics Dominic Risso-Gill Julian Harrison; Director; BTIG LLC Jay Olson Mayank Mamtani Jessica Fye; Analyst; JPMorgan Presentation Operator Good day and thank you...

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...

Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nektar Therapeutics (NASDAQ:NKTR) is advancing its immunology pipeline, focusing on ResPEGaldu leukin (ResPEG) in three separate phase 2 studies. The company plans to share top-line results from a 400-patient phase 2b study...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?